(Q41352179)

29 September 2017

title

Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients (English)

1 reference

29 September 2017

0 references

S Cure

1

1 reference

29 September 2017

I Guerra

series ordinal

2

1 reference

29 September 2017

G Dusheiko

series ordinal

3

1 reference

29 September 2017

publication date

7 April 2015

1 reference

Journal of Viral Hepatitis

29 September 2017

published in

1 reference

29 September 2017

volume

22

1 reference

29 September 2017

issue

11

1 reference

29 September 2017

page(s)

882-889

1 reference

The natural history of hepatitis C virus (HCV) infection

29 September 2017

cites work

1 reference

The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.

21 January 2018

1 reference

Surprisingly small effect of antiviral treatment in patients with hepatitis C.

21 January 2018

1 reference

Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirations

21 January 2018

1 reference

Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.

21 January 2018

1 reference

Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.

21 January 2018

1 reference

Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.

21 January 2018

1 reference

The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States

21 January 2018

1 reference

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

21 January 2018

1 reference

Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice.

21 January 2018

1 reference

Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation.

21 January 2018

1 reference

Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C).

21 January 2018

1 reference

The estimation of a preference-based measure of health from the SF-36.

21 January 2018

1 reference

Estimating the association between SF-12 responses and EQ-5D utility values by response mapping.

21 January 2018

1 reference

Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C.

21 January 2018

1 reference

Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JVH.12409

1 reference

29 September 2017

1 reference